La marque DEMONSTRate: Drug Evalutation in Melanoma: ONcology STudy and Research of Ipilimumab, fondée en 2010 (États-Unis), a 496 marques sœurs et 17478 marques concurrentes. DEMONSTRate: Drug Evalutation in Melanoma: ONcology STudy and Research of Ipilimumab est une marque de la société BRISTOL-MYERS SQUIBB COMPANY, cotée à la bourse de New York. DEMONSTRate: Drug Evalutation in Melanoma: ONcology STudy and Research of Ipilimumab appartient au secteur d’activité Fabricants de médicaments.
L'actualité de la marque DEMONSTRate: Drug Evalutation in Melanoma: ONcology STudy and Research of Ipilimumab
Derniers Tweets
BRISTOL-MYERS SQUIBB COMPANY
(DEMONSTRate: Drug Evalutation in Melanoma: ONcology STudy and Research of Ipilimumab)
.
Toute l'actualité 
BRISTOL-MYERS SQUIBB COMPANY
(DEMONSTRate: Drug Evalutation in Melanoma: ONcology STudy and Research of Ipilimumab)
Derniers Tweets
BRISTOL-MYERS SQUIBB COMPANY
(DEMONSTRate: Drug Evalutation in Melanoma: ONcology STudy and Research of Ipilimumab)
.
Bourse : Plus d'information sur BRISTOL-MYERS SQUIBB COMPANY
(DEMONSTRate: Drug Evalutation in Melanoma: ONcology STudy and Research of Ipilimumab)
